TAGLN2 promotes mesenchymal circulating tumor cell-associated metastasis through the CSNK1E-YAP Axis with concomitant EMT induction and metabolic remodeling in hepatocellular carcinoma.
TAGLN2 protein drives liver cancer spread through a specific cellular pathway, offering a new target for stopping metastasis.
TAGLN2 promotes HCC metastasis by inducing mesenchymal transition of circulating tumor cells via CSNK1E-YAP axis, coupled with EMT and metabolic reprogramming; TAGLN2 represents a novel CTC-specific metastatic driver and therapeutic target. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Mechanistic basic science (in vitro/in vivo)
- Category
- Other
- Maturity
- Exploratory
- Journal
- Cellular signalling
Why it surfaced
Mechanistically novel CTC driver in HCC with potential as a liquid biopsy target; Cellular Signalling publication; TAGLN2-CSNK1E-YAP axis unexplored in prior literature; directly relevant to circulating tumor cell biology in liquid biopsy context.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.